Cutaneous Melanoma - A Review of Systemic Therapies

被引：13

作者：

Lee, Karla A. ^{[1
]}

Nathan, Paul ^{[2
]}

机构：

[1] Kings Coll London, Dept Twin Res, London SE1 9RT, England

[2] Mt Vernon Canc Ctr, Northwood, Middx, England

来源：

ACTA DERMATO-VENEREOLOGICA | 2020年 / 100卷

关键词：

melanoma; systemic therapy; targeted therapy; immunotherapy; DABRAFENIB PLUS TRAMETINIB; LONG-TERM SURVIVAL; STAGE-III; METASTATIC MELANOMA; BRAF INHIBITION; DOUBLE-BLIND; OPEN-LABEL; ADJUVANT IPILIMUMAB; CHOICE CHEMOTHERAPY; COMPLETE RESECTION;

D O I：

10.2340/00015555-3496

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

This decade has brought significantly improved outcomes for patients with advanced melanoma with immunotherapies and targeted treatments offering utility in a variety of settings. In 2020, we can hope for durable long-term responses, and complete remission in a subset of patients with metastatic disease. In the adjuvant setting, approximately 50% improvements in recurrence-free survival are seen both with targeted and immunotherapies. Early data from neoadjuvant immunotherapy clinical trials are very promising. However, responses to treatment are heterogeneous and not always durable; further advances are required, and several emerging strategies are of particular interest. We review the systemic treatment of melanoma, discussing the treatment of unresectable stage III-IV and recurrent disease, outlining curative treatment of cutaneous melanoma in the adjuvant setting and briefly discussing neoadjuvant systemic therapies for advanced melanoma.

引用

页码：291 / 299

页数：9

共 79 条

[1] Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [J].

Amaria, Rodabe N. ;

Reddy, Sangeetha M. ;

Tawbi, Hussein A. ;

Davies, Michael A. ;

Ross, Merrick, I ;

Glitza, Isabella C. ;

Cormier, Janice N. ;

Lewis, Carol ;

Hwu, Wen-Jen ;

Hanna, Ehab ;

Diab, Adi ;

Wong, Michael K. ;

Royal, Richard ;

Gross, Neil ;

Weber, Randal ;

Lai, Stephen Y. ;

Ehlers, Richard ;

Blando, Jorge ;

Milton, Denai R. ;

Woodman, Scott ;

Kageyama, Robin ;

Wells, Daniel K. ;

Hwu, Patrick ;

Patel, Sapna P. ;

Lucci, Anthony ;

Hessel, Amy ;

Lee, Jeffrey E. ;

Gershenwald, Jeffrey ;

Simpson, Lauren ;

Burton, Elizabeth M. ;

Posada, Liberty ;

Haydu, Lauren ;

Wang, Linghua ;

Zhang, Shaojun ;

Lazar, Alexanderj ;

Hudgens, Courtney W. ;

Gopalakrishnan, Vancheswaran ;

Reuben, Alexandre ;

Andrews, Miles C. ;

Spencer, Christine N. ;

Prieto, Victor ;

Sharma, Padmanee ;

Allison, James ;

Tetzlaff, Michael T. ;

Wargo, Jennifer A. .

NATURE MEDICINE, 2018, 24 (11) :1649-+

[2] Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial [J].

Amaria, Rodabe N. ;

Prieto, Peter A. ;

Tetzlaff, Michael T. ;

Reuben, Alexandre ;

Andrews, Miles C. ;

Ross, Merrick J. ;

Glitza, Isabella C. ;

Cormier, Janice ;

Hwu, Wen-Jen ;

Tawbi, Hussein A. ;

Patel, Sapna P. ;

Lee, Jeffrey E. ;

Gersbenwaid, Jeffrey E. ;

Spencer, Christine N. ;

Gopalakrishnan, Vancheswaran ;

Bassett, Roland ;

Simpson, Lauren ;

Mouton, Rosalind ;

Hudgens, Courtney W. ;

Zhao, Li ;

Zhu, Haifeng ;

Cooper, Zachary A. ;

Wani, Khalida ;

Lazar, Alexander ;

Hwu, Patrick ;

Diab, Adi ;

Wong, Michael K. ;

McQuade, Jennifer L. ;

Royal, Richard ;

Lucci, Anthony ;

Burton, Elizabeth M. ;

Reddy, Sangeetha ;

Sharma, Padmanee ;

Allison, James ;

Futreal, Phillip A. ;

Woodman, Scott E. ;

Davies, Michael A. ;

Wargo, Jennifer A. .

LANCET ONCOLOGY, 2018, 19 (02) :181-193

[3] Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma [J].

Andtbacka, Robert H., I ;

Collichio, Frances ;

Harrington, Kevin J. ;

Middleton, Mark R. ;

Downey, Gerald ;

Ohrling, Katarina ;

Kaufman, Howard L. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[4] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[5] Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma [J].

Ascierto, Paolo A. ;

Dummer, Reinhard ;

Gogas, Helen J. ;

Flaherty, Keith T. ;

Arance, Ana ;

Mandala, Mario ;

Liszkay, Gabriella ;

Garbe, Claus ;

Schadendorf, Dirk ;

Krajsova, Ivana ;

Gutzmer, Ralf ;

de Groot, Jan Willem B. ;

Loquai, Carmen ;

Gollerkeri, Ashwin ;

Pickard, Michael D. ;

Robert, Caroline .

EUROPEAN JOURNAL OF CANCER, 2020, 126 :33-44

[6] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial [J].

Ascierto, Paolo A. ;

Long, Georgina V. ;

Robert, Caroline ;

Brady, Benjamin ;

Dutriaux, Caroline ;

Di Giacomo, Anna Maria ;

Mortier, Laurent ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Kalinka-Warzocha, Ewa ;

Savage, Kerry J. ;

Hernberg, Micaela M. ;

Lebbe, Celeste ;

Charles, Julie ;

Mihalcioiu, Catalin ;

Chiarion-Sileni, Vanna ;

Mauch, Cornelia ;

Cognetti, Francesco ;

Ny, Lars ;

Arance, Ana ;

Svane, Inge Marie ;

Schadendorf, Dirk ;

Gogas, Helen ;

Saci, Abdel ;

Jiang, Joel ;

Rizzo, Jasmine ;

Atkinson, Victoria .

JAMA ONCOLOGY, 2019, 5 (02) :187-194

[7] Immunological effects of BRAF plus MEK inhibition [J].

Ascierto, Paolo A. ;

Dummer, Reinhard .

ONCOIMMUNOLOGY, 2018, 7 (09)

[8] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma [J].

Ascierto, Paolo Antonio ;

Ferrucci, Pier Francesco ;

Fisher, Rosalie ;

Del Vecchio, Michele ;

Atkinson, Victoria ;

Schmidt, Henrik ;

Schachter, Jacob ;

Queirolo, Paola ;

Long, Georgina V. ;

Di Giacomo, Anna Maria ;

Svane, Inge Marie ;

Lotem, Michal ;

Bar-Sela, Gil ;

Couture, Felix ;

Mookerjee, Bijoyesh ;

Ghori, Razi ;

Ibrahim, Nageatte ;

Moreno, Blanca Homet ;

Ribas, Antoni .

NATURE MEDICINE, 2019, 25 (06) :941-+

[9] Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade [J].

Boasberg, Peter ;

Hamid, Omid ;

O'Day, Steven .

SEMINARS IN ONCOLOGY, 2010, 37 (05) :440-449

[10] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study [J].

Chapman, P. B. ;

Robert, C. ;

Larkin, J. ;

Haanen, J. B. ;

Ribas, A. ;

Hogg, D. ;

Hamid, O. ;

Ascierto, P. A. ;

Testori, A. ;

Lorigan, P. C. ;

Dummer, R. ;

Sosman, J. A. ;

Flaherty, K. T. ;

Chang, I. ;

Coleman, S. ;

Caro, I. ;

Hauschild, A. ;

McArthur, G. A. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2581-2587

← 1 2 3 4 5 6 7 8 →